The European Commission has approved osimertinib (Tagrisso) as a frontline treatment for patients with EGFR-mutant locally-advanced or metastatic non–small cell lung cancer.
Original Article: Frontline Osimertinib Approved in Europe for EGFR-mutant NSCLC